Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

(2020) Lecia V Sequist et al.   LANCET ONCOLOGY

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

(2020) Alexander Drilon et al.   NATURE MEDICINE

Frequent Mutations of POT1 Distinguish Pulmonary Sarcomatoid Carcinoma From Other Lung Cancer Histologies

(2020) Erica Shen et al.   Clinical Lung Cancer

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

(2020) Paul K. Paik et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma

(2020) Toni K. Choueiri et al.   JAMA Oncology

The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping

(2020) Ravi Salgia et al.   CANCER TREATMENT REVIEWS

Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer

(2020) Jürgen Wolf et al.   NEW ENGLAND JOURNAL OF MEDICINE

MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population

(2019) Jrhau Lung et al.   PLoS One

The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors

(2019) Helei Hou et al.   Cancer Cell International

Response and acquired resistance to savolitinib in a patient with pulmonary sarcomatoid carcinoma harboring MET exon 14 skipping mutation: a case report

(2019) Sen Han et al.   OncoTargets and Therapy

Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer

(2019) M.A. Pruis et al.   LUNG CANCER

Sarcomatoid Carcinoma of the Lung: The Mayo Clinic Experience in 127 Patients

(2018) Kunlatida Maneenil et al.   Clinical Lung Cancer

Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer – A systematic review and meta-analysis

(2018) Huy Gia Vuong et al.   LUNG CANCER

Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer

(2018) De-Shen Wang et al.   GUT

Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer

(2018) Oshin Miranda et al.   Cancers

Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers

(2017) Alexis B. Cortot et al.   JNCI-Journal of the National Cancer Institute

Pulmonary sarcomatoid carcinoma: University of Cincinnati experience

(2017) Nagla Abdel Karim et al.   Oncotarget

Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers

(2017) Alexis B. Cortot et al.   JNCI-Journal of the National Cancer Institute

Characteristics and Clinical Outcomes of Sarcomatoid Carcinoma of the Lung

(2016) Mony Ung et al.   Clinical Lung Cancer

Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations

(2016) Xuewen Liu et al.   JOURNAL OF CLINICAL ONCOLOGY

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations

(2016) Alexa B. Schrock et al.   Journal of Thoracic Oncology

Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors

(2015) G. M. Frampton et al.   Cancer Discovery

Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal–Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer

(2014) Hong Jia et al.   JOURNAL OF MEDICINAL CHEMISTRY

Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models

(2014) Paul R. Gavine et al.   Molecular Oncology

Efficacy of First-Line Chemotherapy in Patients with Advanced Lung Sarcomatoid Carcinoma

(2013) Thibault Vieira et al.   Journal of Thoracic Oncology

An overview of the c-MET signaling pathway

(2011) Shawna Leslie Organ et al.   Therapeutic Advances in Medical Oncology